Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Vahitha B. Abdul-Salam is active.

Publication


Featured researches published by Vahitha B. Abdul-Salam.


Circulation | 2010

Proteomic Analysis of Lung Tissues From Patients With Pulmonary Arterial Hypertension

Vahitha B. Abdul-Salam; J Wharton; John Cupitt; Mark Berryman; Robert J. Edwards; Martin R. Wilkins

Background— Pulmonary arterial hypertension is a disorder of vascular remodeling causing increased resistance to pulmonary blood flow. The expression of proteins in lungs from pulmonary arterial hypertension patients was investigated in an unbiased approach to further understand the pathobiology of this disease. Methods and Results— Label-free liquid chromatography tandem mass spectrometry was used to compare protein profiles in surgical samples of lungs from 8 patients with pulmonary arterial hypertension and 8 control subjects. More than 300 proteins were detected. On the basis of robust criteria, the levels of 25 proteins varied between the 2 groups. The majority of upregulated proteins were associated with cell growth, proliferation, and cell metabolism. Novel findings included an increased expression of chloride intracellular channel 4, receptor for advanced glycation end products, and periostin. Increased expression of chloride intracellular channel 4, a multifunctional protein involved in angiogenesis, and several signaling pathways implicated in pulmonary arterial hypertension—transforming growth factor-&bgr;, vascular endothelial growth factor, and bone morphogenetic protein—was confirmed by Western blotting and localized predominantly to endothelial cells in occlusive and plexiform vascular lesions. Conclusions— Label-free proteomics identified differences in the expression of several proteins in the pulmonary arterial hypertension lung, many of which are relevant to the disease process. Increased expression of chloride intracellular channel 4 may be pertinent to the disorganized angiogenesis of plexiform lesions.


Circulation | 2014

Aberrant Chloride Intracellular Channel 4 Expression Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension

Beata Wojciak-Stothard; Vahitha B. Abdul-Salam; Ka Hou Lao; Hilda Tsang; David Irwin; Christina Lisk; Zoe Loomis; Kurt R. Stenmark; John C. Edwards; Stuart H. Yuspa; Luke Howard; Robert J. Edwards; Christopher J. Rhodes; J. Simon R. Gibbs; John Wharton; Lan Zhao; Martin R. Wilkins

Background— Chloride intracellular channel 4 (CLIC4) is highly expressed in the endothelium of remodeled pulmonary vessels and plexiform lesions of patients with pulmonary arterial hypertension. CLIC4 regulates vasculogenesis through endothelial tube formation. Aberrant CLIC4 expression may contribute to the vascular pathology of pulmonary arterial hypertension. Methods and Results— CLIC4 protein expression was increased in plasma and blood-derived endothelial cells from patients with idiopathic pulmonary arterial hypertension and in the pulmonary vascular endothelium of 3 rat models of pulmonary hypertension. CLIC4 gene deletion markedly attenuated the development of chronic hypoxia-induced pulmonary hypertension in mice. Adenoviral overexpression of CLIC4 in cultured human pulmonary artery endothelial cells compromised pulmonary endothelial barrier function and enhanced their survival and angiogenic capacity, whereas CLIC4 shRNA had an inhibitory effect. Similarly, inhibition of CLIC4 expression in blood-derived endothelial cells from patients with idiopathic pulmonary arterial hypertension attenuated the abnormal angiogenic behavior that characterizes these cells. The mechanism of CLIC4 effects involves p65-mediated activation of nuclear factor-&kgr;B, followed by stabilization of hypoxia-inducible factor-1&agr; and increased downstream production of vascular endothelial growth factor and endothelin-1. Conclusion— Increased CLIC4 expression is an early manifestation and mediator of endothelial dysfunction in pulmonary hypertension.


Arteriosclerosis, Thrombosis, and Vascular Biology | 2016

Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension.

Lulwah Aldabbous; Vahitha B. Abdul-Salam; Tom McKinnon; Lucie Duluc; Joanna Pepke-Zaba; Mark Southwood; Alexander J. Ainscough; Charaka Hadinnapola; Martin R. Wilkins; Mark Toshner; Beata Wojciak-Stothard

Objective— Inflammation and dysregulated angiogenesis are features of endothelial dysfunction in pulmonary hypertension. Neutrophil extracellular traps (NETs), produced by dying neutrophils, contribute to pathogenesis of numerous vascular disorders but their role in pulmonary hypertension has not been studied. We sought evidence of (NETs) formation in pulmonary hypertension and investigated the effect of NETs on endothelial function. Approach and Results— Plasma and lung tissues of patients with pulmonary hypertension were analyzed for NET markers. The effects of NETs on endothelial function were studied in vitro and in vivo. Patients with chronic thromboembolic pulmonary hypertension and idiopathic pulmonary hypertension showed elevated plasma levels of DNA, neutrophil elastase, and myeloperoxidase. NET-forming neutrophils and extensive areas of NETosis were found in the occlusive plexiform lesions and vascularized intrapulmonary thrombi. NETs induced nuclear factor &kgr;B–dependent endothelial angiogenesis in vitro and increased vascularization of matrigel plugs in vivo. Angiogenic responses were associated with increased release of matrix metalloproteinase-9, heparin-binding epidermal growth factor–like growth factor, latency-associated peptide of the transforming growth factor &bgr;1, and urokinase-type plasminogen activator, accompanied by increased endothelial permeability and cell motility. NETs-induced responses depended on myeloperoxidase/H2O2-dependent activation of Toll-like receptor 4/nuclear factor &kgr;B signaling. NETs stimulated the release of endothelin-1 in HPAECs (human pulmonary artery endothelial cells) and stimulated pulmonary smooth muscle cell proliferation in vitro. Conclusions— We are the first to implicate NETs in angiogenesis and provide a functional link between NETs and inflammatory angiogenesis in vitro and in vivo. We demonstrate the potential pathological relevance of this in 2 diseases of disordered vascular homeostasis, pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.


Arteriosclerosis, Thrombosis, and Vascular Biology | 2016

Neutrophil Extracellular Traps Promote Angiogenesis

Lulwah Aldabbous; Vahitha B. Abdul-Salam; Tom McKinnon; Lucie Duluc; Joanna Pepke-Zaba; Mark Southwood; Alexander J. Ainscough; Charaka Hadinnapola; Martin R. Wilkins; Mark Toshner; Beata Wojciak-Stothard

Objective— Inflammation and dysregulated angiogenesis are features of endothelial dysfunction in pulmonary hypertension. Neutrophil extracellular traps (NETs), produced by dying neutrophils, contribute to pathogenesis of numerous vascular disorders but their role in pulmonary hypertension has not been studied. We sought evidence of (NETs) formation in pulmonary hypertension and investigated the effect of NETs on endothelial function. Approach and Results— Plasma and lung tissues of patients with pulmonary hypertension were analyzed for NET markers. The effects of NETs on endothelial function were studied in vitro and in vivo. Patients with chronic thromboembolic pulmonary hypertension and idiopathic pulmonary hypertension showed elevated plasma levels of DNA, neutrophil elastase, and myeloperoxidase. NET-forming neutrophils and extensive areas of NETosis were found in the occlusive plexiform lesions and vascularized intrapulmonary thrombi. NETs induced nuclear factor &kgr;B–dependent endothelial angiogenesis in vitro and increased vascularization of matrigel plugs in vivo. Angiogenic responses were associated with increased release of matrix metalloproteinase-9, heparin-binding epidermal growth factor–like growth factor, latency-associated peptide of the transforming growth factor &bgr;1, and urokinase-type plasminogen activator, accompanied by increased endothelial permeability and cell motility. NETs-induced responses depended on myeloperoxidase/H2O2-dependent activation of Toll-like receptor 4/nuclear factor &kgr;B signaling. NETs stimulated the release of endothelin-1 in HPAECs (human pulmonary artery endothelial cells) and stimulated pulmonary smooth muscle cell proliferation in vitro. Conclusions— We are the first to implicate NETs in angiogenesis and provide a functional link between NETs and inflammatory angiogenesis in vitro and in vivo. We demonstrate the potential pathological relevance of this in 2 diseases of disordered vascular homeostasis, pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.


Arteriosclerosis, Thrombosis, and Vascular Biology | 2010

Identification and Assessment of Plasma Lysozyme as a Putative Biomarker of Atherosclerosis

Vahitha B. Abdul-Salam; Punit Ramrakha; Unni Krishnan; David R. Owen; Joseph Shalhoub; Alun H. Davies; Tjun Y. Tang; Jonathan H. Gillard; Joseph J. Boyle; Martin R. Wilkins; Robert J. Edwards

Objective—To identify a plasma biomarker of atheromatous disease. Methods and Results—Surface-enhanced laser desorption ionization–time-of-flight mass spectrometry was used to identify possible plasma protein biomarkers of atheromatous disease in patients presenting with chronic stable angina pectoris by comparing those with 3-vessel disease with those without any evidence of coronary artery disease. The level of a 14.7-kDa protein was elevated; this protein was isolated and identified as a lysozyme. Arterial plasma lysozyme levels, measured by immunoassay, confirmed this observation in separate cohorts of patients. The application of arterial plasma lysozyme levels to 197 patients with varying degrees of coronary artery disease, using a cutoff value of 1.5 μg/mL, was able to distinguish patients with 1 or more occluded coronary arteries, with 86% sensitivity and 93% specificity. Of 20 patients with carotid atheroma, 19 had increased arterial plasma levels. In contrast, C-reactive protein levels showed no association with disease severity. Venous lysozyme levels in patients with carotid atheroma were shown to decrease after intensive atorvastatin treatment. Conclusion—Raised plasma lysozyme levels may be a useful biomarker of atherosclerotic cardiovascular disease and response to therapy. Additional studies to investigate this are warranted.


Cardiovascular Research | 2017

Tipifarnib prevents development of hypoxia-induced pulmonary hypertension

Lucie Duluc; Blerina Ahmetaj-Shala; Jane A. Mitchell; Vahitha B. Abdul-Salam; Abdul S. Mahomed; Lulwah Aldabbous; Eduardo Oliver; Lucio Iannone; Olivier Dubois; Elisabeth M. Storck; Edward W. Tate; Lan Zhao; Martin R. Wilkins; Beata Wojciak-Stothard

Aims RhoB plays a key role in the pathogenesis of hypoxia-induced pulmonary hypertension. Farnesylated RhoB promotes growth responses in cancer cells and we investigated whether inhibition of protein farnesylation will have a protective effect. Methods and results The analysis of lung tissues from rodent models and pulmonary hypertensive patients showed increased levels of protein farnesylation. Oral farnesyltransferase inhibitor tipifarnib prevented development of hypoxia-induced pulmonary hypertension in mice. Tipifarnib reduced hypoxia-induced vascular cell proliferation, increased endothelium-dependent vasodilatation and reduced vasoconstriction of intrapulmonary arteries without affecting cell viability. Protective effects of tipifarnib were associated with inhibition of Ras and RhoB, actin depolymerization and increased eNOS expression in vitro and in vivo. Farnesylated-only RhoB (F-RhoB) increased proliferative responses in cultured pulmonary vascular cells, mimicking the effects of hypoxia, while both geranylgeranylated-only RhoB (GG-RhoB), and tipifarnib had an inhibitory effect. Label-free proteomics linked F-RhoB with cell survival, activation of cell cycle and mitochondrial biogenesis. Hypoxia increased and tipifarnib reduced the levels of F-RhoB-regulated proteins in the lung, reinforcing the importance of RhoB as a signalling mediator. Unlike simvastatin, tipifarnib did not increase the expression levels of Rho proteins. Conclusions Our study demonstrates the importance of protein farnesylation in pulmonary vascular remodelling and provides a rationale for selective targeting of this pathway in pulmonary hypertension.


Scientific Reports | 2018

Proteomic analysis at the sites of clinical infection with invasive Streptococcus pyogenes

Robert J. Edwards; Marta Pyzio; Magdalena Gierula; Claire E. Turner; Vahitha B. Abdul-Salam; Shiranee Sriskandan

Invasive Streptococcus pyogenes infections are rare, with often-unexplained severity. Prompt diagnosis is desirable, as deaths can occur rapidly following onset and there is an increased, but preventable, risk to contacts. Here, proteomic analyses of clinical samples from invasive human S. pyogenes infections were undertaken to determine if novel diagnostic targets could be detected, and to augment our understanding of disease pathogenesis. Fluid samples from 17 patients with confirmed invasive S. pyogenes infection (empyema, septic arthritis, necrotising fasciitis) were analysed by proteomics for streptococcal and human proteins; 16/17 samples had detectable S. pyogenes DNA. Nineteen unique S. pyogenes proteins were identified in just 6/17 samples, and 15 of these were found in a single pleural fluid sample including streptococcal inhibitor of complement, trigger factor, and phosphoglycerate kinase. In contrast, 469 human proteins were detected in patient fluids, 177 (38%) of which could be identified as neutrophil proteins, including alpha enolase and lactotransferrin which, together, were found in all 17 samples. Our data suggest that streptococcal proteins are difficult to detect in infected fluid samples. A vast array of human proteins associated with leukocyte activity are, however, present in samples that deserve further evaluation as potential biomarkers of infection.


Proteomics | 2006

Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension.

Vahitha B. Abdul-Salam; Gideon A. Paul; J. Omar Ali; Simon Gibbs; Dinah Rahman; Graham W. Taylor; Martin R. Wilkins; Robert J. Edwards


Arteriosclerosis, Thrombosis, and Vascular Biology | 2015

Abstract 230: Protein Farnesylation Inhibitor Tipifarnib Prevents Development of Chronic Hypoxia-induced Pulmonary Hypertension

Lucie Duluc; Blerina Ahmetaj-Shala; Jane A. Mitchell; Vahitha B. Abdul-Salam; Robert J. Edwards; Lulwah Aldabbous; Lucio Iannone; Olivier Dubois; Elisabeth M. Storck; Edward W. Tate; Lan Zhao; Martin R. Wilkins; Beata Wojciak-Stothard


Arteriosclerosis, Thrombosis, and Vascular Biology | 2015

Abstract 202: The Role of Neutrophil Extracellular Traps in the Pathogenesis of Pulmonary Hypertension.

Lulwah Aldabbous; Lucie Duluc; Thomas A. J. McKinnon; Luke Howard; Simon Gibbs; John Wharton; Nicholas W. Morrell; Mark Toshner; Mark Southwood; Joanna Pepke-Zaba; Vahitha B. Abdul-Salam; Martin R. Wilkins; Beata Wojciak-Stothard

Collaboration


Dive into the Vahitha B. Abdul-Salam's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lucie Duluc

Imperial College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lan Zhao

Imperial College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John Wharton

Imperial College London

View shared research outputs
Top Co-Authors

Avatar

Luke Howard

Imperial College Healthcare

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge